NASDAQ:CMPX

Compass Therapeutics News Headlines

$2.80

+0.10 (+3.70%)

(As of 06/24/2022 12:00 AM ET)

Add

Compare

Today's Range: $2.71
▼
$2.84
50-Day Range: $1.43
▼
$3.10
52-Week Range: $1.25
▼
$5.80

Volume: 347,627 shs
Average Volume: 98,536 shs
Market Capitalization: $283.58 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.86

Get Compass Therapeutics News Delivered to You Automatically

CMPX Media Mentions By Week

CMPX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CMPX
News Sentiment
▼
1.01

0.39
▲
Average
Medical
News Sentiment

CMPX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CMPX Articles
This Week
▼
11

1
▲
CMPX Articles
Average Week

CMPX Stock News Headlines Today

Source

Source	Headline
	Equities Analysts Set Expectations for Compass Therapeutics, Inc.'s Q2 2022 Earnings (NASDAQ:CMPX) marketbeat.com - June 24 at 8:17 AM
	Compass Therapeutics, Inc. (NASDAQ:CMPX) CEO Thomas J. Schuetz Acquires 20,000 Shares marketbeat.com - June 21 at 3:21 PM
	B. Riley Comments on Compass Therapeutics, Inc.'s Q2 2022 Earnings (NASDAQ:CMPX) americanbankingnews.com - June 26 at 1:14 AM
	Insider Buying: Compass Therapeutics, Inc. (NASDAQ:CMPX) CEO Acquires 20,000 Shares of Stock americanbankingnews.com - June 20 at 5:13 AM
	Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives $10.00 Average Price Target from Analysts americanbankingnews.com - June 18 at 3:00 AM
	Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Update americanbankingnews.com - June 15 at 6:00 AM
	Compass Therapeutics, Inc. (NASDAQ:CMPX) CEO Buys $68,700.00 in Stock americanbankingnews.com - June 14 at 4:46 AM
	Compass Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference finance.yahoo.com - May 31 at 12:46 PM
	Compass Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference finance.yahoo.com - May 31 at 12:46 PM
	Compass Therapeutics to Present at the 2022 H.C. Wainwright Annual Global Investment Conference finance.yahoo.com - May 23 at 9:34 AM
	Trade Alert: The Co-Founder Of Compass Therapeutics, Inc. (NASDAQ:CMPX), Thomas Schuetz, Has Just Spent US$50k Buying A Few More Shares finance.yahoo.com - May 20 at 11:25 AM

	Entera Bio Board Member, Miranda Toledano, to Assume Role of Chief Business Officer, Chief Financial Officer, and Head of Corporate Strategy finance.yahoo.com - May 16 at 8:08 AM
	Compass Therapeutics stock up 40% in two days following insider buys seekingalpha.com - May 12 at 5:26 PM
	Here's What Compass Therapeutics, Inc.'s (NASDAQ:CMPX) Shareholder Ownership Structure Looks Like finance.yahoo.com - May 9 at 5:10 PM
	Compass Therapeutics to Present at the Bank of America Securities 2022 Healthcare Conference on Thursday, May 12, 2022 at 11:20 a.m. PT finance.yahoo.com - May 5 at 8:29 AM
	Compass Therapeutics to Host Conference Call Highlighting Clinical Data from CTX-009 finance.yahoo.com - May 3 at 6:52 PM
	Compass Therapeutics Announces Appointment of Two New Directors to its Board finance.yahoo.com - April 26 at 10:47 AM
	Compass Therapeutics Announces Appointment of Two New Directors to its Board finance.yahoo.com - April 26 at 10:47 AM
	Compass Therapeutics Presents Data on CTX-8371, a Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting finance.yahoo.com - April 16 at 8:09 AM
	Compass Therapeutics Announces Presentation on CTX-8371, A Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting in New Orleans finance.yahoo.com - March 30 at 12:48 PM
	Compass Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update finance.yahoo.com - March 21 at 12:30 PM
	Compass Therapeutics, Inc. Common Stock (CMPX) nasdaq.com - March 12 at 7:45 PM
	New Capital Management LP Buys Compass Therapeutics Inc, Sells Cambria Shareholder Yield ETF finance.yahoo.com - February 5 at 10:04 AM
	FDA Gives Green Signal To Compass Therapeutics' Mid-Stage Biliary Tract Cancer Trial In US msn.com - January 20 at 12:44 PM
	FDA clears Compass IND for mid-stage study of antibody for biliary tract cancers seekingalpha.com - January 20 at 12:44 PM
	Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 (DLL4) and Vascular Endothelial Growth Factor A (VEGF-A) finance.yahoo.com - January 20 at 12:44 PM
	Compass Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference finance.yahoo.com - January 7 at 10:23 AM
	Compass Therapeutics to Present at the Piper Sandler 33rd Annual Healthcare Conference finance.yahoo.com - November 22 at 1:22 PM
	Compass Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update finance.yahoo.com - November 12 at 9:38 AM
	Do Institutions Own Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares? finance.yahoo.com - November 3 at 11:00 AM
	Compass Therapeutics and ABL Bio Announce Presentation of CTX-009 Clinical Data as a Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics finance.yahoo.com - October 20 at 12:38 PM
	CTX-009 (ABL001/ES104) Clinical Data Presented Today at the New Drugs on the Horizon Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics finance.yahoo.com - October 20 at 12:38 PM

Get Compass Therapeutics News Delivered to You Automatically

This page (NASDAQ:CMPX) was last updated on 6/26/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms